Lexicon Pharmaceuticals LXRX Accrued Manufacturing Costs
Accrued Manufacturing Costs at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's accrued manufacturing costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's accrued manufacturing costs?
- Lexicon Pharmaceuticals (LXRX) reported accrued manufacturing costs of $2.75M in Q1 2026.
- How has Lexicon Pharmaceuticals's accrued manufacturing costs changed year-over-year?
- Lexicon Pharmaceuticals's accrued manufacturing costs decreased by 27.3% year-over-year, from $3.78M to $2.75M.
- What is the long-term trend for Lexicon Pharmaceuticals's accrued manufacturing costs?
- Over 3 years (2022 to 2025), Lexicon Pharmaceuticals's accrued manufacturing costs has grown at a -6.4% compound annual growth rate (CAGR), from $7.83M to $6.42M.